DDX41 and myeloid neoplasm: DDX41 mutation has been reported mainly in about 2%–5% of myeloid neoplasms [2, 3, 4, 5, 6], a few in chronic myeloid leukemia, lymphomas, multiple myeloma, sarcoidosis, and blastic plasmacytoid dendritic cell neoplasm [2, 7].